Literature DB >> 16575845

Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis.

Gerben A Koning1, Raymond M Schiffelers, Marca H M Wauben, Robbert J Kok, Enrico Mastrobattista, Grietje Molema, Timo L M ten Hagen, Gert Storm.   

Abstract

OBJECTIVE: To investigate whether RGD peptide-exposing long circulating polyethylene glycol (PEG) liposomes (RGD-PEG-L) targeted to alphavbeta3 integrins expressed on angiogenic vascular endothelial cells (VECs) are able to bind VECs at sites of inflammation and whether such liposomes containing dexamethasone phosphate (DEXP) can be used as carriers to interfere with the development of experimental arthritis.
METHODS: Binding and internalization of RGD-PEG-L were studied by fluorescence-activated cell sorting and confocal microscopy using fluorescently labeled liposomes. Radiolabeled liposomes were used to test in vivo pharmacokinetics and inflammation site targeting in lipopolysaccharide (LPS)-induced inflammation and adjuvant-induced arthritis (AIA) in rats. In vivo inflammation targeting was visualized by intravital microscopy using fluorescently labeled RGD-PEG-L. Therapeutic efficacy of DEXP-encapsulating RGD-PEG-L compared with nontargeted liposomes was evaluated in rats with AIA.
RESULTS: RGD-PEG-L bound to and were taken up by proliferating human VECs in vitro. In vivo, increased targeting of radiolabeled RGD-PEG-L to areas of LPS-induced inflammation in rats was observed. Specific association with the blood vessel wall at the site of inflammation was confirmed by intravital microscopy. One single intravenous injection of DEXP encapsulated in RGD-PEG-L resulted in a strong and long-lasting antiarthritic effect in rat AIA.
CONCLUSION: RGD-targeted PEG liposomes represent an endothelial cell-specific drug delivery system that targets VECs at sites of inflammation. Use of these liposomes to deliver DEXP to VECs at arthritis-affected sites proved efficacious in rat adjuvant arthritis. These data indicate that VECs have an essential role in the inflammation process and suggest the possibility of using VEC targeting for therapeutic intervention in inflammatory processes such as arthritis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16575845     DOI: 10.1002/art.21719

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  47 in total

Review 1.  Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.

Authors:  Israel Rubinstein; Guy L Weinberg
Journal:  Nanomedicine       Date:  2012-05-26       Impact factor: 5.307

Review 2.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

3.  Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy.

Authors:  Rakeshchandra R Meka; Shivaprasad H Venkatesha; Bodhraj Acharya; Kamal D Moudgil
Journal:  Nanomedicine (Lond)       Date:  2019-04-02       Impact factor: 5.307

4.  Dynamic imaging of arginine-rich heart-targeted vehicles in a mouse model.

Authors:  Hua Zhang; Jiro Kusunose; Azadeh Kheirolomoom; Jai W Seo; Jinyi Qi; Katherine D Watson; Heather A Lindfors; Erkki Ruoslahti; Julie L Sutcliffe; Katherine W Ferrara
Journal:  Biomaterials       Date:  2008-02-06       Impact factor: 12.479

Review 5.  Nanocarriers for vascular delivery of anti-inflammatory agents.

Authors:  Melissa D Howard; Elizabeth D Hood; Blaine Zern; Vladimir V Shuvaev; Tilo Grosser; Vladimir R Muzykantov
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 6.  Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior.

Authors:  Miles A Miller; Ralph Weissleder
Journal:  Adv Drug Deliv Rev       Date:  2016-06-04       Impact factor: 15.470

Review 7.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

Review 8.  Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis.

Authors:  Gustav J Strijkers; Ewelina Kluza; Geralda A F Van Tilborg; Daisy W J van der Schaft; Arjan W Griffioen; Willem J M Mulder; Klaas Nicolay
Journal:  Angiogenesis       Date:  2010-06       Impact factor: 9.596

Review 9.  Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.

Authors:  Wiebke Ulbrich; Alf Lamprecht
Journal:  J R Soc Interface       Date:  2009-11-25       Impact factor: 4.118

10.  Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes.

Authors:  Geralda A F van Tilborg; Willem J M Mulder; Daisy W J van der Schaft; Chris P M Reutelingsperger; Arjan W Griffioen; Gustav J Strijkers; Klaas Nicolay
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.